View in EDS HTML Full Text PDF Full Text

Comparative cardiovascular risks of canagliflozin and selective SGLT2 inhibitors in type 2 diabetes.

Saved in:
Bibliographic Details
Title: Comparative cardiovascular risks of canagliflozin and selective SGLT2 inhibitors in type 2 diabetes.
Authors: Kornelius E; Chung Shan Medical University, School of Medicine, Taichung, Taiwan.; Chung Shan Medical University Hospital, Department of Internal Medicine, Division of Endocrinology and Metabolism, Taichung, Taiwan., Lo SC; Chung Shan Medical University Hospital, Department of Internal Medicine, Division of Endocrinology and Metabolism, Taichung, Taiwan., Yang YS; Chung Shan Medical University, School of Medicine, Taichung, Taiwan.; Chung Shan Medical University Hospital, Department of Internal Medicine, Division of Endocrinology and Metabolism, Taichung, Taiwan., Wang YH; Chung Shan Medical University Hospital, Department of Medical Research, Taichung, Taiwan., Huang CN; Chung Shan Medical University, School of Medicine, Taichung, Taiwan.; Chung Shan Medical University Hospital, Department of Internal Medicine, Division of Endocrinology and Metabolism, Taichung, Taiwan.; Chung Shan Medical University, Institute of Medicine, Taichung, Taiwan.
Source: Frontiers in pharmacology [Front Pharmacol] 2025 Oct 20; Vol. 16, pp. 1686851. Date of Electronic Publication: 2025 Oct 20 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41190032
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Comparative cardiovascular risks of canagliflozin and selective SGLT2 inhibitors in type 2 diabetes.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kornelius+E%22">Kornelius E</searchLink>; Chung Shan Medical University, School of Medicine, Taichung, Taiwan.; Chung Shan Medical University Hospital, Department of Internal Medicine, Division of Endocrinology and Metabolism, Taichung, Taiwan.<br /><searchLink fieldCode="AU" term="%22Lo+SC%22">Lo SC</searchLink>; Chung Shan Medical University Hospital, Department of Internal Medicine, Division of Endocrinology and Metabolism, Taichung, Taiwan.<br /><searchLink fieldCode="AU" term="%22Yang+YS%22">Yang YS</searchLink>; Chung Shan Medical University, School of Medicine, Taichung, Taiwan.; Chung Shan Medical University Hospital, Department of Internal Medicine, Division of Endocrinology and Metabolism, Taichung, Taiwan.<br /><searchLink fieldCode="AU" term="%22Wang+YH%22">Wang YH</searchLink>; Chung Shan Medical University Hospital, Department of Medical Research, Taichung, Taiwan.<br /><searchLink fieldCode="AU" term="%22Huang+CN%22">Huang CN</searchLink>; Chung Shan Medical University, School of Medicine, Taichung, Taiwan.; Chung Shan Medical University Hospital, Department of Internal Medicine, Division of Endocrinology and Metabolism, Taichung, Taiwan.; Chung Shan Medical University, Institute of Medicine, Taichung, Taiwan.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101548923%22">Frontiers in pharmacology</searchLink> [Front Pharmacol] 2025 Oct 20; Vol. 16, pp. 1686851. <i>Date of Electronic Publication: </i>2025 Oct 20 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Media]%22">Frontiers Media] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101548923 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1663-9812 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216639812%22">16639812 </searchLink><i>NLM ISO Abbreviation: </i>Front Pharmacol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41190032
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fphar.2025.1686851
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1686851
    Titles:
      – TitleFull: Comparative cardiovascular risks of canagliflozin and selective SGLT2 inhibitors in type 2 diabetes.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kornelius E
      – PersonEntity:
          Name:
            NameFull: Lo SC
      – PersonEntity:
          Name:
            NameFull: Yang YS
      – PersonEntity:
          Name:
            NameFull: Wang YH
      – PersonEntity:
          Name:
            NameFull: Huang CN
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 20
              M: 10
              Text: 2025 Oct 20
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 1663-9812
          Numbering:
            – Type: volume
              Value: 16
          Titles:
            – TitleFull: Frontiers in pharmacology
              Type: main
ResultId 1